RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/22791810http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/22791810http://www.w3.org/2000/01/rdf-schema#comment"The adaptor protein regulator for ubiquitous kinase/c-Cbl-interacting protein of 85kDa (Ruk/CIN85) was found to modulate HER1/EGFR signaling and processes like cell adhesion and apoptosis. Although these features imply a role in carcinogenesis, it is so far unknown how and by which molecular mechanisms Ruk/CIN85 could affect a certain tumor phenotype. By analyzing samples from breast cancer patients, we found high levels of Ruk(l)/CIN85 especially in lymph node metastases from patients with invasive breast adenocarcinomas, suggesting that Ruk(l)/CIN85 contributes to malignancy. Expression of Ruk(l)/CIN85 in weakly invasive breast adenocarcinoma cells deficient of Ruk(l)/CIN85 indeed converted them into more malignant cells. In particular, Ruk(l)/CIN85 reduced the growth rate, decreased cell adhesion, enhanced anchorage-independent growth, increased motility in both transwell migration and wound healing assays as well as affected the response to epidermal growth factor. Thereby, Ruk(l)/CIN85 led to a more rapid and prolonged epidermal growth factor-dependent activation of Src, Akt and ERK1/2 and treatment with the Src inhibitor PP2 and the PI3K inhibitor LY294002 abolished the Ruk(l)/CIN85-dependent changes in cell motility. Together, this study indicates that high levels of Ruk(l)/CIN85 contribute to the conversion of breast adenocarcinoma cells into a more malignant phenotype via modulation of the Src/Akt pathway."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.org/dc/terms/identifier"doi:10.1093/carcin/bgs228"xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Kietzmann T."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Drobot L."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Buchman V."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Volodko N."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Samoylenko A."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Lyzogubov V."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Usenko V."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Kozlova N."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Byts N."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Barska M."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Basaraba O."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Bobak Y."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Mayevska O."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Palyvoda K."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Pasichnyk G."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Rzhepetsky Y."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Savran V."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Shuvayeva H."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/author"Vynnytska-Myronovska B."xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/date"2012"xsd:gYear
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/name"Carcinogenesis"xsd:string
http://purl.uniprot.org/citations/22791810http://purl.uniprot.org/core/pages"1976-1984"xsd:string